IL17A and Alzheimer disease: Intriguingly, EAE mice modified to abolish IL-17 production, as well as AD models treated with neutralizing antibodies against IL-17, show delayed clinical progression, confirming the harmful effects of IL-17 in EAE and suggesting that Th17 cells also contribute to the progression of AD (171).